# Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

> **NCT00093704** · PHASE1 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Lymphoma
- Lymphoproliferative Disorder

## Interventions

- **DRUG:** bortezomib + ganciclovir

## Key facts

- **NCT ID:** NCT00093704
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** study could not recruit any more patients
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093704, "Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00093704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*